← Eichor
Study identifier: NCT06909877 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

Condition: Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)  ·  Sponsor: Haihe Biopharma Co., Ltd.

PhasePhase 1/Phase 2
Planned participants100
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.

This description comes directly from the study's public registry record.

Talk to the study team

Haiying Jia  ·  86-20568888  ·  haiying.jia@haihepharma.com

Always discuss trial participation with your own doctor first.

Locations (1)

Sichuan Cancer HospitalChengdu, Chengdu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06909877